VINC
Vincerx Pharma, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.01
+0.00%Income statement
| Metric | TTM | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1.1M | — | — | — | — |
| Cost of Revenue | 826.0K | 1.1M | 915.0K | 939.0K | 340.0K |
| Gross Profit | (11.0K) | (1.1M) | (915.0K) | (939.0K) | (340.0K) |
| Operating Expenses | |||||
| R&D Expense | 11.9M | 15.5M | 28.1M | 52.2M | 40.1M |
| SG&A Expense | 15.4M | 16.0M | 13.6M | 19.0M | 22.6M |
| General & Admin Expense | 15.4M | 16.0M | 13.6M | 19.0M | 22.6M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 27.3M | 31.5M | 41.7M | 71.1M | 62.7M |
| Cost and Expenses | 27.3M | 31.5M | 42.6M | 71.1M | 62.7M |
| Operating Income (EBIT) | (27.3M) | (31.5M) | (42.6M) | (68.7M) | (62.7M) |
| Non-Operating | |||||
| Interest Income | 373.0K | 472.0K | 1.3M | 664.0K | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | 373.0K | 472.0K | 1.3M | 664.0K | — |
| Other Non-Op Income/Expense | 4.7M | 1.4M | 2.5M | 5.7M | 23.4M |
| Non-Operating Income (excl Interest) | — | — | (2.5M) | (5.7M) | (23.4M) |
| EBT (Pre-Tax Income) | (22.6M) | (30.1M) | (40.2M) | (63.0M) | (39.3M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (22.6M) | (30.1M) | (40.2M) | (65.4M) | (39.3M) |
| Earnings from Cont. Ops | (22.6M) | (30.1M) | (40.2M) | (63.0M) | (39.3M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (22.6M) | (30.1M) | (40.2M) | (63.0M) | (39.3M) |
| Per Share | |||||
| Basic EPS | ($4.22) | ($5.75) | ($6.84) | ($10.86) | ($8.30) |
| Diluted EPS | ($4.22) | ($5.75) | ($6.84) | ($10.86) | ($8.30) |
| Revenue Per Share | $0.20 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 5.2M | 5.2M | 5.9M | 5.8M | 4.7M |
| Diluted Shares Outstanding | 5.2M | 5.2M | 5.9M | 5.8M | 4.7M |
| Profitability Metrics | |||||
| EBITDA | (26.5M) | (31.5M) | (39.2M) | (62.0M) | (39.0M) |
| D&A | 839.0K | 1.1M | 915.0K | 939.0K | 340.0K |
| EBIT | (27.3M) | (31.5M) | (40.2M) | (63.0M) | (39.3M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2025